Clinical Trial Update: Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations [Phase 3]

View source ↗

Summary

Phase 3 trial comparing QVA149 (indacaterol/glycopyrronium) against NVA237 (glycopyrronium) and tiotropium on COPD exacerbations; results posted following compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• NVA237
• QVA149 (indacaterol/glycopyrronium)
• tiotropium (tiotropium)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Obstructive Pulmonary Disease | Phase 3 | Status: COMPLETED | Results posted: 2013-09-30